UK's Lord Warner adds conviction to government's HITF (Healthcare Industries Task Force) pledges
This article was originally published in Clinica
The forthcoming transfer of the UK's Device Evaluation Service from the Medicines and Healthcare products Regulatory Agency (MHRA) to the NHS Purchasing and Supplies Agency (PaSA) is the leading development right now in the UK healthcare industry's plans to strengthen and raise the profile of the national medical technology activity.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.